Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)
Antineoplastic Combined Chemotherapy Protocols
Neoplasm Recurrence, Local
Vatalanib was well tolerated as a second-line therapy and resulted in favorable 6-month survival rate in patients with metastatic pancreatic cancer, compared with historic controls.
PubMed Central ID
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency